Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn, Anton Pozniak, Horacio Mingrone, +18

The Lancet

Treatment And PreventionWeek 48Antiviral Drug DevelopmentAntiviral TherapyDolutegravir Versus Raltegravir +5

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas, +204

The Lancet

Hiv/aids CounsellingTreatment And PreventionWeek 48Clinical EpidemiologyClinical Trials +12

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

David A. Margolis, Cynthia Brinson, Graham Smith, +13

The Lancet Infectious Diseases

Phase 2BHuman RetrovirusPharmacologyAntiviral Drug DevelopmentAntiviral Therapy +8

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten, +11

The Lancet HIV

Week 96Treatment And PreventionAntiviral Drug DevelopmentAntiviral TherapyVirology +7

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax, +132

The Lancet HIV

Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyNon-inferiority Trial +5

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Chloe Orkin, Edwin DeJesus, Paul E. Sax, +18

The Lancet HIV

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax, +135

The Lancet HIV

Treatment And PreventionAntiretroviral-naive AdultsClinical TrialsAntiviral Drug DevelopmentAntiviral Therapy +4

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study

Kathleen Squires, Cissy Kityo, Sally Hodder, +10

The Lancet HIV

Treatment And PreventionMedicineImmunologyAntiviral TherapyHiv-1 Infected Women +5

Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study

Bisher Akil, Gary Blick, Debbie Hagins, +8

Antiviral Therapy

Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients

Josep M. Gatell, Javier O Morales‐Ramirez, Debbie Hagins, +10

Journal of the International AIDS Society